<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A series of 90 rats underwent a duodenoesophageal reflux surgery were divided into 2 groups: the control group was given a commercial chow and the <z:chebi fb="0" ids="41423">celecoxib</z:chebi> group experimental chow containing <z:chebi fb="0" ids="41423">celecoxib</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>The animals were sacrificed sequentially every 10 weeks after surgery </plain></SENT>
<SENT sid="2" pm="."><plain>In the control group, <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, columnar-lined epithelium (CLE) and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> (<z:chebi fb="49" ids="35181">ADC</z:chebi>) were first observed at the 10th, 20th, and 30th week, respectively, and their incidences sequentially increased and reached 100%, 89% and 47% at the 40th week, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>In the <z:chebi fb="0" ids="41423">celecoxib</z:chebi> group, the <z:hpo ids='HP_0100633'>esophagitis</z:hpo> was mild and the incidence of CLE was significantly lower at each week compared with the control group </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="49" ids="35181">ADC</z:chebi> was not observed in the <z:chebi fb="0" ids="41423">celecoxib</z:chebi> group throughout the experiment </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="41423">Celecoxib</z:chebi> suppressed <z:hpo ids='HP_0100633'>esophagitis</z:hpo> and subsequent CLE and <z:chebi fb="49" ids="35181">ADC</z:chebi> in rats </plain></SENT>
</text></document>